Trust specifics

Deposit information
- Public offering price per unit: $10.00
- Minimum investment ($250 for IRAs): $1,000.00
- Deposit date: 11/09/23
- Termination date: 11/13/25
- Distribution dates: 25th day of March, June, September, and December
- Record dates: 10th day of March, June, September, and December
- Term of trust: 24 months
- Symbol: IHCBCK

Historical 12 month distributions: $0.0748

HCRX234 Sales charge and CUSIPs

Brokerage Sales charge³
- Deferred sales charge: 2.25%
- Creation and development fee: 0.50%
- Total sales charge: 2.75%
- Last deferred sales charge payment date: 08/10/24

CUSIPs
- Cash: 46147T-S8-2
- Reinvest: 46147T-S9-0

Historical 12 month distribution rate: 0.74%

Fee-based Sales charge³
- Fee-based sales charge: 0.50%

CUSIPs
- Fee-based cash: 46147T-60-8
- Fee-based reinvest: 46147T-61-6

Historical 12 month distribution rate: 0.77%

The trust portfolio is provided for informational purposes only and should not be deemed as a recommendation to buy or sell the individual securities shown above.

Objective

The Portfolio seeks capital appreciation. The Portfolio seeks to achieve its objective by investing in a portfolio primarily consisting of stocks of companies diversified within the healthcare industry.

Portfolio composition (As of the business day before deposit date)

Biotechnology
- AbbVie, Inc.: ABBV
- CSL, Ltd. - ADR: CSLLY
- Regeneron Pharmaceuticals, Inc.: REGN
- Vertex Pharmaceuticals, Inc.: VRTX

Health Care Distributors
- Henry Schein, Inc.: HSIC
- McKesson Corporation: MCK

Health Care Equipment
- Boston Scientific Corporation: BSX
- Edwards Lifesciences Corporation: EW
- IDEXX Laboratories, Inc.: IDXX
- Intuitive Surgical, Inc.: ISRG
- Medtronic plc: MDT
- Stryker Corporation: SYK

Health Care Services
- Cigna Group: CI
- CVS Health Corporation: CVS
- DaVita, Inc.: DVA

Life Sciences Tools & Services
- Danaher Corporation: DHR
- Repligen Corporation: RGEN
- Thermo Fisher Scientific, Inc.: TMO
- West Pharmaceutical Services, Inc.: WST

Managed Health Care
- Centene Corporation: CNC
- Elevance Health, Inc.: ELV
- Humana, Inc.: HUM
- UnitedHealth Group, Inc.: UNH

Pharmaceuticals
- Eli Lilly and Company: LLY
- Johnson & Johnson: JNJ
- Merck & Company, Inc.: MRK
- Novo Nordisk A/S - ADR CL B: NVO
- Roche Holding AG - ADR: RHHBY
- Zoetis, Inc.: ZTS

See page 2 for the footnotes on trust specifics.

Not a Deposit Not FDIC Insured Not Guaranteed by the Bank May Lose Value Not Insured by any Federal Government Agency
Portfolio selection
The companies selected for the Portfolio may share a variety of traits, among others, as of the time of selection, such as:

- Innovative products and services
- Operations within a market with high barriers to entry
- Ownership of highly valuable intangible assets such as patents and intellectual property
- FactSet Estimates* consensus analyst recommendation of "Hold" or better
- Attractive balance sheets
- Well-capitalized

*FactSet Estimates is a database that provides detail-level estimates and recommendations from many different contributing firms. FactSet Estimates translates the data into a uniform consensus average recommendation from the contributing firms.

About risk
There is no assurance the trust will achieve its investment objective. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the trust will decline and that the value of trust units may therefore be less than what you paid for them. This trust is unmanaged and its portfolio is not intended to change during the trust's life except in limited circumstances. Accordingly, you can lose money investing in this trust. The trust should be considered as part of a long-term investment strategy and you should consider your ability to pursue it by investing in successive trusts, if available. You will realize tax consequences associated with investing from one series to the next.

The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your Units. This may occur at any point in time, including during the initial offering period.

You could experience dilution of your investment if the size of the Portfolio is increased as Units are sold. There is no assurance that your investment will maintain its proportionate share in the Portfolio's profits and losses.

A portfolio concentrated in a single market sector presents more risk than a portfolio broadly diversified over several market sectors. The Portfolio is concentrated in securities issued by companies in the health care industry. Companies involved in advanced medical devices and instruments, hospital management and biotechnology face risks such as extensive competition, product liability litigation, and evolving government regulation. Negative developments in the health care industry will affect the value of your investment more than would be the case in a more diversified investment.

Investing in companies operating in foreign countries involves certain risks not typically associated with investing solely in the United States. This may magnify volatility due to changes in foreign exchange rates, the political and economic uncertainties in foreign countries, and the potential lack of liquidity, government supervision and regulation.

Common stocks do not assure dividend payments. Dividends are paid only when declared by an issuer's board of directors and the amount of any dividend may vary over time. There can be no guarantee or assurance that companies will declare dividends in the future or that if declared, they will remain at current levels or increase over time.

1 Including sales charges. As of deposit date.
2 Represents the value of 100 units on the deposit date. The value of the minimum investment amount of 100 units may be greater or less than $1,000.00 following the deposit date.
3 Assuming a public offering price of $10 per unit. There is no initial sales charge if the public offering price per unit is $10 or less. If the public offering price per unit exceeds $10, an initial sales charge is paid at the time of purchase. The per unit amount of the initial sales charge is 2.75% of the dollar amount that the public offering price per unit exceeds $10.

Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the trust, investors should ask their financial professional(s) for a prospectus or download one at invesco.com/uit.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Invesco unit investment trusts are distributed by the Sponsor, Invesco Capital Markets, Inc. and broker dealers including Invesco Distributors, Inc. Both firms are indirect, wholly owned subsidiaries of Invesco Ltd.

Diversified Healthcare Portfolio 2023-4
invesco.com/uit
U-HCRX234-FCT-1 11/23